Daniel L J Thorek

List of Publications by Year
in descending order

48	1,916	279487 23	264894 42
papers	citations	h-index	g-index

50	50	50	3869
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Translational Medicine, 2018, 7, 651-663.	1.6	192
2	Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nature Communications, 2014, 5, 3097.	5.8	139
3	Quantitative imaging of disease signatures through radioactive decay signal conversion. Nature Medicine, 2013, 19, 1345-1350.	15.2	138
4	NGF-TrkA Signaling by Sensory Nerves Coordinates the Vascularization and Ossification of Developing Endochondral Bone. Cell Reports, 2016, 16, 2723-2735.	2.9	134
5	Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E11238-E11247.	3.3	125
6	Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Science Translational Medicine, 2016, 8, 331ra39.	5.8	88
7	Fatty acid oxidation by the osteoblast is required for normal bone acquisition in a sex- and diet-dependent manner. JCI Insight, 2017, 2, .	2.3	84
8	In vivo radiometric analysis of glucose uptake and distribution in mouse bone. Bone Research, 2016, 4, 16004.	5.4	83
9	Whole-Body and Microenvironmental Localization of Radium-223 in NaÃ¯ve and Mouse Models of Prostate Cancer Metastasis. Journal of the National Cancer Institute, 2016, 108, djv380.	3.0	81
10	Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. European Urology, 2019, 76, 170-176.	0.9	71
11	Tumorâ€infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?. Prostate, 2019, 79, 320-330.	1.2	58
12	Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Research, 2019, 79, 3636-3650.	0.4	47
13	Towards the stable chelation of radium for biomedical applications with an 18-membered macrocyclic ligand. Chemical Science, 2021, 12, 3733-3742.	3.7	46
14	Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Thrombosis and Haemostasis, 2013, 110, 484-492.	1.8	43
15	Deconvoluting hepatic processing of carbon nanotubes. Nature Communications, 2016, 7, 12343.	5.8	42
16	Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist. Journal of Nuclear Medicine, 2015, 56, 805-811.	2.8	39
17	Listening to membrane potential: photoacoustic voltage-sensitive dye recording. Journal of Biomedical Optics, 2017, 22, 045006.	1.4	38
18	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications, 2018, 9, 1629.	5.8	37

#	Article	IF	Citations
19	Contemporary approaches for imaging skeletal metastasis. Bone Research, 2015, 3, 15024.	5.4	33
20	A Radium-223 microgenerator from cyclotron-produced trace Actinium-227. Applied Radiation and Isotopes, 2017, 119, 36-42.	0.7	33
21	Molecularly specific detection of bacterial lipoteichoic acid for diagnosis of prosthetic joint infection of the bone. Bone Research, 2018, 6, 13.	5.4	29
22	Molecular Imaging Using Nanoparticle Quenchers of Cerenkov Luminescence. Small, 2014, 10, 3729-3734.	5.2	28
23	Noninvasive optical and nuclear imaging of Staphylococcus-specific infection with a human monoclonal antibody-based probe. Virulence, 2018, 9, 262-272.	1.8	27
24	Mouse model of Gram-negative prosthetic joint infection reveals therapeutic targets. JCI Insight, 2018, 3, .	2.3	25
25	Prostate Cancer Theranostics - An Overview. Frontiers in Oncology, 2020, 10, 884.	1.3	24
26	Internalization of secreted antigenâ€“targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Science Translational Medicine, 2016, 8, 367ra167.	5.8	23
27	Dawn of Advanced Molecular Medicine: Nanotechnological Advancements in Cancer Imaging and Therapy. Critical Reviews in Oncogenesis, 2014, 19, 143-176.	0.2	22
28	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clinical Cancer Research, 2019, 25, 881-891.	3.2	21
29	Carbon nanotubes exhibit fibrillar pharmacology in primates. PLoS ONE, 2017, 12, e0183902.	1.1	18
30	Voltage-sensitive dye delivery through the blood brain barrier using adenosine receptor agonist regadenoson. Biomedical Optics Express, 2018, 9, 3915.	1.5	17
31	The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates. Nuclear Medicine and Biology, 2018, 62-63, 1-8.	0.3	14
32	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060.	3.2	13
33	Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. European Urology, 2015, 68, 1076-1082.	0.9	12
34	Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models. International Journal of Radiation Oncology Biology Physics, 2015, 93, 444-453.	0.4	12
35	Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. Immunotherapy, 2021, 13, 155-175.	1.0	12
36	Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics, 2021, 11, 9721-9737.	4.6	12

#	Article	IF	Citations
37	PSMA expression in the Hiâ€Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool. Prostate, 2019, 79, 678-685.	1.2	10
38	Improved ²²³Ra Therapy with Combination Epithelial Sodium Channel Blockade. Journal of Nuclear Medicine, 2021, 62, 1751-1758.	2.8	10
39	Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution. Nuclear Medicine and Biology, 2015, 42, 375-380.	0.3	9
40	Stable Chelation of the Uranyl Ion by Acyclic Hexadentate Ligands: Potential Applications for 230U Targeted Î±-Therapy. Inorganic Chemistry, 2022, , .	1.9	7
41	Preclinical Single Photon Emission Computed Tomography of Alpha Particle-Emitting Radium-223. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 520-529.	0.7	6
42	A Projection-Domain Low-Count Quantitative SPECT Method for É‘-Particle-Emitting Radiopharmaceutical Therapy. IEEE Transactions on Radiation and Plasma Medical Sciences, 2023, 7, 62-74.	2.7	4
43	Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINEâ€1 ctDNA: A comparison to standard methods. Prostate, 2021, 81, 745-753.	1.2	3
44	Blind Image Restoration Enhances Digital Autoradiographic Imaging of Radiopharmaceutical Tissue Distribution. Journal of Nuclear Medicine, 2022, 63, 591-597.	2.8	2
45	Predilection for developing a hematogenous orthopaedic implant-associated infection in older versus younger mice. Journal of Orthopaedic Surgery and Research, 2021, 16, 556.	0.9	2
46	Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 355-363.	0.7	2
47	Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmÃ¶ preventive project. Oncotarget, 2018, 9, 5778-5785.	0.8	1
48	Assessment of Lexiscan for Blood Brain Barrier disruption to facilitate Fluorescence brain imaging. , 2017, , .		0